BNTC
Benitec Biopharma Inc.
Healthcare — Biotechnology
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Price History
Fundamentals
| Market Cap | $435.96M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.35 |
| EPS (TTM) | $-0.93 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -29.58% |
| Debt/Equity | 0.48 |
| Recommendation | Strong Buy 1.2 |
| Analyst Target | $25.80 |
| Analysts | 5 |
| Next Earnings | Sep 14, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 67.3 |
| Beta | 0.28 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $16.76 |
| 52-Week Low | $9.85 |
| 50-Day Avg | $11.81 |
| 200-Day Avg | $12.52 |
| Avg Volume | 111.4K |
| Volume | 61.7K |
Performance Analysis
BULLISHBNTC shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:00 UTC
Back to Screener Export Report